Thursday, July 26, 2018

LA BioMed spinoff, Emmaus Life Sciences has announced that The New England Journal of Medicine has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.

Tuesday, July 24, 2018

Newly published study shows that strategies to curb inappropriate antibiotic prescribing which lead to deadly antibiotic resistant superbugs that kill an estimated 23,000 people each year are not only successful but also cost effective.

Wednesday, June 20, 2018
A researcher from LA BioMed has been awarded $688,013 in grant funding from the National Institutes of Health to improve newborn infant screening.
Thursday, June 7, 2018

RB-A Render

From cancer-fighting therapies to groundbreaking models for emergency care and nursing, the Los Angeles Biomedical Research Institute (LA BioMed) has been home to some of modern medicine's most important breakthroughs.  

Wednesday, February 7, 2018

Torrance, CA (February 7, 2018): Calling the day a “major milestone,” Los Angeles County Supervisor Mark Ridley-Thomas joined officials of LA BioMed for the topping off ceremony of their 78,000 square foot research building and incubator that is an integral component of LA County’s 1st Biotech Hub, emerging in the heart of LA BioMed’s 11.5-acre research park adjacent to Harbor-UCLA Medical Center in Torrance.

Friday, July 7, 2017

News provided by U.S. Food and Drug Administration

July 7, 2017

The U.S. Food and Drug Administration today approved Endari (L-glutamine oral powder) for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder.

Friday, June 16, 2017

Offers Additional Resources to Help its Startups Succeed

LOS ANGELES – (June 16, 2017) – LA BioMed is launching a Commercialization Accelerator Program™ (CAP), designed and implemented by Larta Institute, that will offer LA BioMed’s early stage bioscience companies additional resources to strengthen and speed their innovations to the marketplace, Keith B. Hoffman, PhD, LA BioMed vice president of business development and technology transfer, and Rohit Shukla,  Larta Institute CEO, announced today.